Clinical Trials Search
HORMONET: Phase II Study of Hormone Therapy with Tamoxifen in Patients with well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
This is a single-arm, single-stage clinical study of tamoxifen for patients with well-differentiated neuroendocrine tumors and radiological progression with positive (> 1%) HR (estrogen and/or progesterone) expression by immunohistochemistry (IHC).
Primary: To evaluate the efficacy of tamoxifen in patients with NETs that are well-differentiated, express HRs (estrogen and/or progesterone receptor), and are progressing. Secondary: (1) to evaluate progression-free survival; (2) to evaluate biochemical response; (3) objective response rate; (4) disease control rate according to HR expression intensity and primary site; (5) toxicities.